These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24285767)

  • 21. A prospective multicentre study on the treatment of cardiovascular risk factors and claudication symptoms in patients with peripheral artery disease (the IDOMENEO study).
    Cimminiello C; Arpaia G; Polo Friz H; Boracchi P; Marano G; Spezzigu G; Visonà A
    Vasa; 2015 Sep; 44(5):371-9. PubMed ID: 26317257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Not Available].
    Füessl HS
    MMW Fortschr Med; 2013 May; 155(10):34. PubMed ID: 23930415
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of ramipril on renal function in patients with intermittent claudication.
    Hobbs SD; Claridge MW; Wilmink AB; Adam DJ; Thomas ME; Bradbury AW
    Vasc Health Risk Manag; 2008; 4(2):471-5. PubMed ID: 18561523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A meta-analysis of the outcome of endovascular and noninvasive therapies in the treatment of intermittent claudication.
    Ahimastos AA; Pappas EP; Buttner PG; Walker PJ; Kingwell BA; Golledge J
    J Vasc Surg; 2011 Nov; 54(5):1511-21. PubMed ID: 21958561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk.
    Sipahi I; Chou J; Mishra P; Debanne SM; Simon DI; Fang JC
    Am J Cardiol; 2011 Jul; 108(2):294-301. PubMed ID: 21600543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peripheral arterial disease: a review of disease awareness and management.
    Watson K; Watson BD; Pater KS
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):365-79. PubMed ID: 17296541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of relationship between gait parameters and physical function in peripheral arterial disease.
    Scherer SA; Hiatt WR; Regensteiner JG
    J Vasc Surg; 2006 Oct; 44(4):782-8. PubMed ID: 17012002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An integrative review: application of self-efficacy instruments for walking in populations with peripheral arterial disease.
    Caldieraro-Bentley AJ; Andrews JO
    J Vasc Nurs; 2013 Sep; 31(3):118-30. PubMed ID: 23953861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
    Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How To Assess a Claudication and When To Intervene.
    Hossain P; Kokkinidis DG; Armstrong EJ
    Curr Cardiol Rep; 2019 Nov; 21(12):138. PubMed ID: 31728766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial.
    Ahimastos AA; Lawler A; Reid CM; Blombery PA; Kingwell BA
    Ann Intern Med; 2006 May; 144(9):660-4. PubMed ID: 16670135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future perspectives.
    Kaur P; Muthuraman A; Kaur M
    ACS Chem Neurosci; 2015 Apr; 6(4):508-21. PubMed ID: 25680080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.
    Dinicolantonio JJ; Lavie CJ; O'Keefe JH
    Postgrad Med; 2013 Jul; 125(4):154-68. PubMed ID: 23933903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ramipril for the prevention and treatment of cardiovascular disease.
    Vuong AD; Annis LG
    Ann Pharmacother; 2003 Mar; 37(3):412-9. PubMed ID: 12639174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease.
    Meng Y; Squires H; Stevens JW; Simpson E; Harnan S; Thomas S; Michaels J; Stansby G; O'Donnell ME
    Angiology; 2014 Mar; 65(3):190-7. PubMed ID: 23378195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Peripheral arterial disease: Treatment].
    Desormais I; Aboyans V; Pesteil F; Lacroix P
    Presse Med; 2018 Jan; 47(1):56-61. PubMed ID: 29273182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
    Epstein BJ; Gums JG
    Ann Pharmacother; 2005 Mar; 39(3):470-80. PubMed ID: 15701766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The US experience with cilostazol in treating intermittent claudication.
    Hiatt WR
    Atheroscler Suppl; 2005 Dec; 6(4):21-31. PubMed ID: 16275166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.